Korean biotech firms are seen as undervalued by big investment firms
10-Apr-17, Business Korea
Domestic smaller biotech companies are drawing much interest by attracting huge investment from foreign investors.
According to an industry source, “Biotech firms in South Korea are second to none in the world in terms of technology but their values have been underestimated due to the small size of the domestic market.”
%20Business%20Korea.jpg "Korean biotech firms are seen as undervalued by big investment firms (c) Business Korea")
Image: Business Korea
Biopharmaceutical manufacturer Hugel announced it has resolved to carry out capital increase through third-party allocation worth KRW455 bn (USD404 mn) with respect to Bain Capital.
Binex, a Korean contract manufacturer, attracted an investment of KRW210 bn (USD186 mn) in Nov-16 from Tsinghua Tongfang Group, a state-run Chinese company.